Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer

BACKGROUND: Consolidation treatment with an anti-PD-L1 antibody, durvalumab, following concurrent chemo-radiotherapy (cCRT) has become a new standard of care for locally advanced non-small cell lung cancer (NSCLC). The rationale of PD-L1 blockade after cCRT is based on preclinical evidence suggestin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoneda, Kazue, Kuwata, Taiji, Kanayama, Masatoshi, Mori, Masataka, Kawanami, Toshinori, Yatera, Kazuhiro, Ohguri, Takayuki, Hisaoka, Masanori, Nakayama, Toshiyuki, Tanaka, Fumihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738061/
https://www.ncbi.nlm.nih.gov/pubmed/31388183
http://dx.doi.org/10.1038/s41416-019-0541-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738061/
https://www.ncbi.nlm.nih.gov/pubmed/31388183
http://dx.doi.org/10.1038/s41416-019-0541-3

Ejemplares similares